share_log

Johnson & Johnson | 4: Statement of changes in beneficial ownership of securities-Officer REED JOHN C

Johnson & Johnson | 4: Statement of changes in beneficial ownership of securities-Officer REED JOHN C

強生 | 4：持股變動聲明-高管 REED JOHN C
美股sec公告 ·  05/04 04:37
牛牛AI助理已提取核心訊息
On May 1, 2024, John C. Reed, EVP of Innovative Medicine, R&D at Johnson & Johnson, completed a stock transaction involving the company's common stock. Reed executed a sale of 10,984 shares at a price of $144.59 per share, resulting in a total transaction value of $1,588,176.56. Prior to this sale, Reed acquired 22,255 shares through the exercise of derivative securities at no cost. Following these transactions, Reed's direct holdings in Johnson & Johnson common stock amounted to 11,577 shares.
On May 1, 2024, John C. Reed, EVP of Innovative Medicine, R&D at Johnson & Johnson, completed a stock transaction involving the company's common stock. Reed executed a sale of 10,984 shares at a price of $144.59 per share, resulting in a total transaction value of $1,588,176.56. Prior to this sale, Reed acquired 22,255 shares through the exercise of derivative securities at no cost. Following these transactions, Reed's direct holdings in Johnson & Johnson common stock amounted to 11,577 shares.
2024年5月1日，強生公司創新醫學研發執行副總裁約翰·裏德完成了一項涉及公司普通股的股票交易。裏德以每股144.59美元的價格出售了10,984股股票，總交易價值爲1,588,176.56美元。在此次出售之前，裏德通過行使衍生證券免費收購了22,255股股票。這些交易之後，裏德直接持有的強生普通股爲11,577股。
2024年5月1日，強生公司創新醫學研發執行副總裁約翰·裏德完成了一項涉及公司普通股的股票交易。裏德以每股144.59美元的價格出售了10,984股股票，總交易價值爲1,588,176.56美元。在此次出售之前，裏德通過行使衍生證券免費收購了22,255股股票。這些交易之後，裏德直接持有的強生普通股爲11,577股。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。